RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to RBC Capital Positive on Kempharm (KMPH) Amid KP201 Tamper Study Results

KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP

September 30, 2015 7:31 AM EDT

CORALVILLE, Iowa, Sept. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported positive results from three distinct studies designed to evaluate the tamper-resistant properties of its lead opioid prodrug KP201/APAP, KemPharm's prodrug of hydrocodone in combination with acetaminophen (APAP) compared to a generic hydrocodone bitartrate/APAP product (HB/APAP). The studies were designed based on feedback from the U.S. Food and Drug Administration (FDA). KemPharm believes that, together with the positive data from KemPharm's previous human abuse... More